616 related articles for article (PubMed ID: 25461655)
1. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
Kassamali Z; Jain R; Danziger LH
Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
[TBL] [Abstract][Full Text] [Related]
2. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
Kassamali Z; Danziger L
Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
[TBL] [Abstract][Full Text] [Related]
3. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
[TBL] [Abstract][Full Text] [Related]
4. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
5. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.
Cheah SE; Li J; Tsuji BT; Forrest A; Bulitta JB; Nation RL
Antimicrob Agents Chemother; 2016 Jul; 60(7):3921-33. PubMed ID: 27067324
[TBL] [Abstract][Full Text] [Related]
6. Colistin: an update on the antibiotic of the 21st century.
Biswas S; Brunel JM; Dubus JC; Reynaud-Gaubert M; Rolain JM
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):917-34. PubMed ID: 23030331
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
[TBL] [Abstract][Full Text] [Related]
8. Polymyxin B versus colistin: an update.
Cai Y; Lee W; Kwa AL
Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
[TBL] [Abstract][Full Text] [Related]
9. The use of polymyxins to treat carbapenem resistant infections in neonates and children.
Thomas R; Velaphi S; Ellis S; Walker AS; Standing JF; Heath P; Sharland M; Dona' D
Expert Opin Pharmacother; 2019 Mar; 20(4):415-422. PubMed ID: 30576264
[TBL] [Abstract][Full Text] [Related]
10. Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.
Tran TB; Cheah SE; Yu HH; Bergen PJ; Nation RL; Creek DJ; Purcell A; Forrest A; Doi Y; Song J; Velkov T; Li J
J Antibiot (Tokyo); 2016 Jun; 69(6):415-21. PubMed ID: 26669752
[TBL] [Abstract][Full Text] [Related]
11. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
12. Rational use of intravenous polymyxin B and colistin: A review.
Zakuan ZD; Suresh K
Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
[TBL] [Abstract][Full Text] [Related]
14. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
[TBL] [Abstract][Full Text] [Related]
15. Colistin and polymyxin B: peas in a pod, or chalk and cheese?
Nation RL; Velkov T; Li J
Clin Infect Dis; 2014 Jul; 59(1):88-94. PubMed ID: 24700659
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii.
Chung JH; Bhat A; Kim CJ; Yong D; Ryu CM
Sci Rep; 2016 Jun; 6():28168. PubMed ID: 27306928
[TBL] [Abstract][Full Text] [Related]
17. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
18. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
[TBL] [Abstract][Full Text] [Related]
19. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea.
Ko KS; Suh JY; Kwon KT; Jung SI; Park KH; Kang CI; Chung DR; Peck KR; Song JH
J Antimicrob Chemother; 2007 Nov; 60(5):1163-7. PubMed ID: 17761499
[TBL] [Abstract][Full Text] [Related]
20. Comparative Evaluation of Broth Microdilution with Polystyrene and Glass-Coated Plates, Agar Dilution, E-Test, Vitek, and Disk Diffusion for Susceptibility Testing of Colistin and Polymyxin B on Carbapenem-Resistant Clinical Isolates of Acinetobacter baumannii.
Singhal L; Sharma M; Verma S; Kaur R; Britto XB; Kumar SM; Ray P; Gautam V
Microb Drug Resist; 2018 Oct; 24(8):1082-1088. PubMed ID: 29406804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
